JPH0599919A - Leukocyte analyzing method - Google Patents

Leukocyte analyzing method

Info

Publication number
JPH0599919A
JPH0599919A JP9055991A JP9055991A JPH0599919A JP H0599919 A JPH0599919 A JP H0599919A JP 9055991 A JP9055991 A JP 9055991A JP 9055991 A JP9055991 A JP 9055991A JP H0599919 A JPH0599919 A JP H0599919A
Authority
JP
Japan
Prior art keywords
fluorescence
acridine orange
leukocyte
solution
staining solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP9055991A
Other languages
Japanese (ja)
Other versions
JPH07113632B2 (en
Inventor
Hideyuki Horiuchi
秀之 堀内
Ryohei Yabe
良平 矢部
Shinichi Sakuraba
伸一 桜庭
Norio Kaneko
紀夫 金子
Nobuyuki Tatara
信之 多田羅
Hiroshi Oki
博 大木
Isao Yamazaki
功夫 山崎
Akira Miyake
亮 三宅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hitachi Instruments Engineering Co Ltd
Hitachi Ltd
Original Assignee
Hitachi Instruments Engineering Co Ltd
Hitachi Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hitachi Instruments Engineering Co Ltd, Hitachi Ltd filed Critical Hitachi Instruments Engineering Co Ltd
Priority to JP3090559A priority Critical patent/JPH07113632B2/en
Publication of JPH0599919A publication Critical patent/JPH0599919A/en
Publication of JPH07113632B2 publication Critical patent/JPH07113632B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)

Abstract

PURPOSE:To realize the classification of five kinds of the normal leukocytes by using acridine orange fluorescence staining solution containing acridine orange fluorescence dyestuff, buffer solution whose pH is higher than physiological pH and physiological isotonic osmotic pressure reagent as analyzing fluorescence staining solution. CONSTITUTION:When leukocyte is stained with acridine orange staining agent, the leukocyte is bonded with neucleuses present in the leukocyte and granules present in cytoplasma. The green or red fluorescence is generated. The neucleus of the cell is mainly constituted of DNA. When the neucleus is bonded with the acridine orange, the green fluorescence indicating the maximum value in the vicinity of 530nm is generated. The granule present in the cytoplasma contains RNA. Therefore, the red fluorescence having the maximum value in the vicinity of 640nm is generated. The osmotic pressure of the acridine orange fluorescence staining solution is set in the vicinity of 290mosm/kg of physiological osmotic pressure. The pH of fluorescence solution is set at a value higher than the normal physiological pH. Thus, the five of the normal leukocytes can be classified. Furthermore, a small amount of erythrocyte hemolysis agent is added into the staining solution. Thus, the surface of the cell cytoplasmic membrane of the leukocyte is changed. In this way, the fluoresence intensity is increased at normal temperature and the staining time is shortened.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、白血球分析方法に係
り、特に、病院における血液学検査項目のうち白血球を
分類するための白血球分析方法に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a leukocyte analysis method, and more particularly to a leukocyte analysis method for classifying leukocytes among hematology test items in hospitals.

【0002】[0002]

【従来の技術】白血球分類法について説明する。通常、
血液中の白血球には、正常な白血球として、好中球、好
酸球、好塩基球、単球、リンパ球の5種類のものがあ
る。このうち好中球と好酸球と好塩基球をまとめて顆粒
球という。これらの5種類の白血球は、通常末梢血に現
れる正常な白血球である。これらの正常白血球以外に、
通常末梢血には現れない異常血球として、異型リンパ
球、幼若顆粒球、芽球等がある。
2. Description of the Related Art A white blood cell classification method will be described. Normal,
There are five types of normal white blood cells as neutrophils, eosinophils, basophils, monocytes, and lymphocytes as normal white blood cells. Among them, neutrophils, eosinophils and basophils are collectively called granulocytes. These five types of white blood cells are normal white blood cells that normally appear in peripheral blood. Besides these normal white blood cells,
Abnormal blood cells that do not usually appear in peripheral blood include atypical lymphocytes, immature granulocytes, blasts and the like.

【0003】従来、白血球分類を始めとする血液像検査
は、顕微鏡下で人の目視による血球形態の観察、分類と
いう形で行われてきた。この方法は、顕微鏡観察による
人の判断に基づいて行われるため、分類処理速度が遅
く、また目の疲労も大きい。更に、検査技師間の分類解
釈の相違、処理血球数が少ないことに起因して、統計的
誤差が大きいなどの問題があった。
Conventionally, blood image examinations such as white blood cell classification have been performed in the form of observing and classifying blood cell morphology by human visual observation under a microscope. Since this method is performed based on a person's judgment by microscopic observation, the classification processing speed is slow and eye fatigue is large. Furthermore, there are problems such as a large statistical error due to the difference in classification and interpretation between the laboratory technicians and the small number of blood cells to be processed.

【0004】そこで、血液像検査の自動処理装置が提案
される。従来の典型的な自動処理装置で利用される方法
としては、顕微鏡画像のパターン認識手法による血球分
類方法である。この方法は、人間の目の代わりにTV撮
像装置を用いて、顕微鏡像を電気信号に変換し、コンピ
ュータ等による画像処理・パターン認識処理を行う。処
理速度は人間よりも速いが、処理血球数を飛躍的に多く
することはできない。血液標本作成のために、メイ・ギ
ムザ染色等による前処理に20〜30分の時間を要し、
全体の処理効率は、人間が処理する場合と大きく変わら
ない。処理血球数が少ないことに起因する統計的誤差
は、特に少数血球の検査では、目視の場合と同様に大き
い。少数血球の例としては、単球、好酸球、好塩基球な
どの正常血球と、異型リンパ球、幼若顆粒球、芽球など
の異常血球がある。
Therefore, an automatic blood image processing apparatus is proposed. A method used in a conventional typical automatic processing apparatus is a blood cell classification method by a pattern recognition method of a microscope image. In this method, a TV image pickup device is used instead of human eyes, a microscopic image is converted into an electric signal, and image processing / pattern recognition processing is performed by a computer or the like. The processing speed is faster than that of humans, but the number of processed blood cells cannot be increased dramatically. For blood sample preparation, it takes 20 to 30 minutes for pretreatment with May-Giemsa staining, etc.
The overall processing efficiency is not much different from human processing. The statistical error due to the small number of treated blood cells is as large as the case of visual inspection, especially in the examination of a few blood cells. Examples of the minority blood cells include normal blood cells such as monocytes, eosinophils and basophils, and abnormal blood cells such as atypical lymphocytes, immature granulocytes and blasts.

【0005】上記の問題を考慮して、最近ではフローサ
イトメータに代表される手法、すなわち血球にレーザ光
を照射し、血球からの光散乱、光透過、蛍光強度の各信
号を使い、更に従来から行われている血球カウンタによ
る電気抵抗情報を加え、これらのパラメータから血球分
類を行うフロー方式が提案されている。これらの装置に
関しては、特開昭49−89390号、特開昭61−8
8896号、特表昭61−502277号、特開昭54
−14957号等の先行文献が存在する。
In consideration of the above problems, recently, a method typified by a flow cytometer, that is, a blood cell is irradiated with a laser beam and signals of light scattering, light transmission, and fluorescence intensity from the blood cell are used. A flow system has been proposed in which blood cell classification is performed from these parameters by adding electrical resistance information by a blood cell counter. Regarding these devices, JP-A-49-89390 and JP-A-61-8
8896, Tokushusho No. 61-502277, JP-A-54
There are prior documents such as -14957.

【0006】これらの装置の特徴は、血球浮遊液をフロ
ーセル中に流し、一個一個の血球からの散乱情報及び蛍
光情報を用いて処理するため、処理血球の個数が非常に
多く統計的誤差が小さく、前処理時間が短いこと、更に
再現性がよく、目視との相関の良い結果が得られるとい
った利点がある。
The features of these devices are that the hemocyte suspension is flown into the flow cell and processed using scattered information and fluorescence information from each hemocyte, so the number of hemocytes treated is very large and the statistical error is small. In addition, there are advantages that the pretreatment time is short, the reproducibility is good, and the result is well correlated with visual observation.

【0007】[0007]

【発明が解決しようとする課題】しかしながら、上述し
たフロー方式による白血球分類法には、以下に示す問題
がある。電気インピーダンスや光散乱パラメータ等を利
用した白血球分類法では、血球サイズ情報と血球の全体
的な電気的性質とを利用するため、血球間の微妙な違い
を識別することが困難である。特に、好塩基球、好酸
球、単球に関しては、リンパ球又は好中球と識別するこ
とが困難な場合がある。また、これら少数血球の分類精
度が、統計的に期待される精度よりも悪いことがある。
更に、異常球では幼若顆粒球、異型リンパ球等の正しい
分類比率を知ることができない。加えて、この方法で
は、特殊な試薬を必要としたり、試薬の調合・分析方法
に工夫が必要である。そこで、上記のフロー方式白血球
分類法では、フロー方式の上記問題を改善するため、更
に、予め蛍光色素により血球を染色し、レーザ光による
蛍光強度の大小から白血球分類を行うといった方法が提
案される。蛍光色素の代表的なものにアクリジンオレン
ジがある。この方法では、蛍光色素が、血球種類による
細胞質のRNAや核のDNAに取り込まれる量の違い
を、緑及び赤の蛍光強度の大きさから調べ、血球を分類
する。この方法によれば、蛍光色素の細胞膜透過性の違
いも影響するため、白血球の各血球種の違いを明瞭に知
ることができる。この方法に関して、生理学pH及び低
張溶液を使用し、染料の吸収が平衡に達する前に測定す
る方法は、特開昭50−75473号(特公昭59−8
53号)公報に開示され、染色液を生理学的条件である
等張溶液を使用する方法は特開昭47−3049号公報
に開示される。しかし、上記の等張溶液を使用する方法
の場合には、白血球は顆粒球、単球、リンパ球の3分類
しかできないという不具合があった。一方、低張溶液を
使用する方法の場合には、白血球は正常な血球につき5
分類と幼若顆粒球の検出が可能であるが、低張染色条件
だけでは次のような問題があった。 (1) 白血球細胞に損傷が生じることがある。 (2) 赤の蛍光強度は一般に緑の蛍光強度に比較して
弱く、色素が赤血球にも一部吸収されて赤の蛍光を発
し、白血球からの蛍光信号を妨害する。 (3) 白血球と赤血球の比率は500:1であり、染
色溶液の希釈倍率も小さいため赤血球同時通過が非常に
多く、この赤血球の存在により白血球からの蛍光信号が
影響を受ける。 (4) その結果、特に、単球とリンパ球の区別を正し
く行うことができない場合がある。 本発明の目的は、上記諸問題に鑑み、等張溶液を利用し
た白血球分類法であっても、5種類の正常な白血球の分
類を実現し、更に異常球、特に異型リンパ球、幼若顆粒
球の分類、及び血小板凝集のある標本の検出を可能とす
る白血球分析方法を提供することにある。
However, the white blood cell classification method by the above-mentioned flow method has the following problems. In the white blood cell classification method that uses electrical impedance, light scattering parameters, and the like, it is difficult to identify a subtle difference between blood cells because it uses blood cell size information and the overall electrical properties of blood cells. In particular, basophils, eosinophils, and monocytes may be difficult to distinguish from lymphocytes or neutrophils. Moreover, the classification accuracy of these minority blood cells may be worse than the statistically expected accuracy.
Furthermore, the abnormal classification ratio of immature granulocytes, atypical lymphocytes, etc. cannot be known from abnormal spheres. In addition, this method requires a special reagent, and requires devising a method for preparing and analyzing the reagent. Therefore, in the above-mentioned flow method white blood cell classification method, in order to improve the above problems of the flow method, a method is proposed in which blood cells are dyed in advance with a fluorescent dye and white blood cell classification is performed based on the magnitude of fluorescence intensity by laser light. .. Acridine orange is a typical fluorescent dye. In this method, the difference in the amount of fluorescent dye incorporated into cytoplasmic RNA or nuclear DNA depending on the blood cell type is examined from the magnitudes of green and red fluorescence intensities to classify blood cells. According to this method, the difference in the cell membrane permeability of the fluorescent dye also affects, so that the difference in the blood cell types of white blood cells can be clearly known. Regarding this method, a method of using physiological pH and a hypotonic solution and measuring before the dye absorption reaches equilibrium is disclosed in JP-A-50-75473 (Japanese Patent Publication No. 59-8).
No. 53), and a method of using an isotonic solution under physiological conditions as a staining solution is disclosed in JP-A-47-3049. However, in the case of using the above-mentioned isotonic solution, there is a problem that leukocytes can be classified into only three types, granulocytes, monocytes and lymphocytes. On the other hand, when the hypotonic solution is used, the white blood cells are 5 per normal blood cell.
Although it is possible to classify and detect juvenile granulocytes, there were the following problems only with hypotonic staining conditions. (1) White blood cells may be damaged. (2) The red fluorescence intensity is generally weaker than the green fluorescence intensity, and the dye is partially absorbed by red blood cells to emit red fluorescence, which interferes with the fluorescence signal from white blood cells. (3) Since the ratio of white blood cells to red blood cells is 500: 1 and the dilution ratio of the staining solution is small, the simultaneous passage of red blood cells is very large, and the presence of these red blood cells affects the fluorescence signal from the white blood cells. (4) As a result, in particular, it may not be possible to correctly distinguish between monocytes and lymphocytes. In view of the above problems, an object of the present invention is to achieve classification of 5 types of normal leukocytes even with a leukocyte classification method using an isotonic solution, and further to provide abnormal spheres, particularly atypical lymphocytes and immature granules. It is an object of the present invention to provide a leukocyte analysis method which enables classification of spheres and detection of specimens having platelet aggregation.

【0008】[0008]

【課題を解決するための手段】本発明に係る白血球分析
方法は、レーザ光を利用するフロー式の白血球分析方法
であり、予め白血球を染色するための分析蛍光染色溶液
として、 (1)アクリジンオレンジ蛍光染料 (2)溶液pHが生理的pHより高い緩衝液 (3)生理的等張浸透圧 からなる試薬を含むアクリジンオレンジ蛍光染色溶液を
使用し、白血球からの緑色蛍光及び赤色蛍光による蛍光
信号の大小により、血液中の白血球の分類を行うことを
特徴とする。
The leukocyte analysis method according to the present invention is a flow-type leukocyte analysis method utilizing laser light, which is (1) acridine orange as an analytical fluorescent staining solution for previously staining leukocytes. Fluorescent dye (2) Buffer solution whose pH is higher than physiological pH (3) Acridine orange fluorescent staining solution containing a reagent consisting of physiological isotonic osmotic pressure is used, and the fluorescence signals of green fluorescence and red fluorescence from white blood cells are detected. The feature is that white blood cells in blood are classified according to size.

【0009】上記の如く、本発明の白血球分析方法で使
用する染色剤はアクリジンオレンジであり、一般に異染
性蛍光染料として知られている。この染色剤で白血球を
染色した場合、白血球内に存在する核や細胞質に存在す
る顆粒と結合して、緑色又は赤色の蛍光が発生する。細
胞の核は主としてDNAで構成され、アクリジンオレン
ジと結合すると530nm付近に極大値を有する緑色蛍
光を出す。一方、細胞質に存在する顆粒は、RNAを含
むことから640nm付近に極大を有する赤色蛍光を発
する。レーザ光源としては、アクリジンオレンジの吸収
極大波長480nm付近に発振線があるアルゴンイオン
レーザが適している。
As described above, the staining agent used in the leukocyte analysis method of the present invention is acridine orange, which is generally known as a metachromatic fluorescent dye. When leukocytes are stained with this stain, they bind to the nuclei present in leukocytes and the granules present in the cytoplasm to generate green or red fluorescence. The cell nucleus is mainly composed of DNA, and when it binds to acridine orange, it emits green fluorescence having a maximum value around 530 nm. On the other hand, since the granules present in the cytoplasm contain RNA, they emit red fluorescence having a maximum at around 640 nm. As a laser light source, an argon ion laser having an oscillation line near the absorption maximum wavelength of 480 nm of acridine orange is suitable.

【0010】第1の課題である5種類の正常白血球の分
類することの解決としては、アクリジンオレンジ蛍光染
色溶液の浸透圧を生理的浸透圧290mosm/kg付
近に設定し、染色溶液のpHを生理的正常pHより高く
(8.4〜8.9)設定することで、5種類の正常白血
球を分類できることを見い出した。
As a solution to the classification of the five types of normal white blood cells which is the first problem, the osmotic pressure of the acridine orange fluorescent staining solution is set to a physiological osmotic pressure of about 290 mosm / kg, and the pH of the staining solution is adjusted to physiological. It was found that five types of normal white blood cells can be classified by setting the pH higher than the normal normal pH (8.4 to 8.9).

【0011】更に、上記染色溶液に赤血球溶血剤を少量
添加することにより、白血球の細胞膜表面を変化させ、
染色溶液の血球への吸収を促進する効果を持たせた結
果、常温でありながら蛍光強度の増大、染色時間の短縮
化が可能となった。溶血剤としては、例えばサポニン等
が使用され、添加割合として0.025〜0.035重
量%である。
Furthermore, by adding a small amount of an erythrocyte hemolyzing agent to the above staining solution, the cell membrane surface of leukocytes is changed,
As a result of having the effect of promoting the absorption of the staining solution into blood cells, it became possible to increase the fluorescence intensity and shorten the staining time even at room temperature. As the hemolytic agent, for example, saponin or the like is used, and the addition ratio is 0.025 to 0.035% by weight.

【0012】他の課題である大量赤血球同時通過による
白血球信号への影響の排除については、上記赤血球溶血
剤の作用により赤血球を破壊するので、この赤血球によ
る赤色蛍光信号への妨害効果及び光散乱の影響を減少さ
せることができた。このため問題になっていた単球とリ
ンパ球の分離が良くなり、これら血球の分類正確度と再
現性が向上する。赤血球を十分溶血させる濃度に設定す
れば、白血球からの光散乱情報を利用することができ、
蛍光情報と併せて分類パラメータが増大した分だけ識別
精度が向上する。しかし、更に高濃度では白血球にも影
響が現れ、白血球分類そのものにも影響が現れる。
In order to eliminate the influence of the simultaneous passage of a large amount of red blood cells on the white blood cell signal, which is another problem, the red blood cell is destroyed by the action of the red blood cell hemolyzing agent. The impact could be reduced. As a result, the problematic separation of monocytes and lymphocytes is improved, and the classification accuracy and reproducibility of these blood cells are improved. If the concentration is set to sufficiently lyse red blood cells, light scattering information from white blood cells can be used,
The identification accuracy improves as much as the classification parameter increases together with the fluorescence information. However, at higher concentrations, white blood cells will be affected, and the white blood cell classification itself will be affected.

【0013】また白血球分類の具体的な処理は次の通り
である。先ず血球からの蛍光を、光フィルターで緑色及
び赤色の蛍光に分離し、光検出器で電気信号に変換した
後、データ処理装置で分類作業を行う。次に、各血球か
ら得られた緑色及び赤色蛍光強度信号に関する2次元サ
イトグラムを作ると、正常白血球5種類について各血球
ごとに特徴あるクラスラを有するパターンが生じる。こ
のパターンから各白血球の分類を行う。
The specific processing of white blood cell classification is as follows. First, fluorescence from blood cells is separated into green and red fluorescence by an optical filter, converted into an electric signal by a photodetector, and then classified by a data processing device. Next, when a two-dimensional cytogram concerning the green and red fluorescence intensity signals obtained from each blood cell is created, a pattern having a characteristic clathra for each blood cell is generated for five types of normal white blood cells. Each white blood cell is classified from this pattern.

【0014】本発明による染色溶液の条件では、正常白
血球の5分類のクラスタばかりでなく、幼若顆粒球、異
型リンパ球などもそれぞれ独自の位置にクラスタを形成
するため、これらの異常球の分類も可能となる。また芽
球が存在する血液標本では、独自のサイトグラムがで
き、これは正常白血球だけのサイトグラムと大きく異な
るため、先の幼若顆粒球及び異型リンパ球と共に異常球
を含む血液標本を見つけることができる。更に、血小板
凝集のある血液標本では、血小板凝集独特のサイトグラ
ムを生じるため、血小板凝集のある検体の検出も可能で
ある。
Under the conditions of the staining solution according to the present invention, not only five normal white blood cell clusters but also juvenile granulocytes, atypical lymphocytes, etc. form clusters at their own positions. Will also be possible. In addition, a blood sample containing blast cells has its own cytogram, which is very different from the cytogram of normal white blood cells only.Therefore, it is necessary to find a blood sample containing abnormal lymphocytes as well as immature granulocytes and atypical lymphocytes. You can Furthermore, since a cytogram peculiar to platelet aggregation is generated in a blood sample with platelet aggregation, it is possible to detect a sample with platelet aggregation.

【0015】[0015]

【作用】本発明による白血球分析方法では、上述したア
クリジンオレンジを主成分とした染色溶液を使用した白
血球分類法にて、等張溶液を使用するため、従来行われ
ていた低張条件における白血球破壊が起こらず、正確な
白血球分類を行うことが可能である。しかも等張条件で
は従来3分類しかできなかったものを、本発明では正常
白血球5分類を行うことが可能となった。
In the leukocyte analysis method according to the present invention, since the isotonic solution is used in the leukocyte classification method using the above-mentioned staining solution containing acridine orange as a main component, leukocyte destruction under hypotonic conditions that has been conventionally performed. It is possible to perform accurate white blood cell classification without causing Moreover, in the present invention, the normal white blood cells can be classified into 5 categories, whereas the conventional method could only classify into 3 categories under the isotonic condition.

【0016】更に、少量の赤血球溶血剤を本発明による
染色溶液に添加することにより、蛍光強度の増大、染色
時間の短縮化が図られ、赤血球の影響を小さくすること
により、単球とリンパ球の識別が容易になった。
Furthermore, by adding a small amount of an erythrocyte hemolyzing agent to the staining solution of the present invention, the fluorescence intensity is increased and the staining time is shortened. By reducing the influence of erythrocytes, monocytes and lymphocytes are reduced. It became easier to identify.

【0017】また、本発明の染色溶液を使用することに
より、正常白血球5分類ばかりでなく、異常血球のうち
異型リンパ球及び幼若顆粒球の分類が可能になった。芽
球を始め、血小板凝集のある血液標本にたいしては、正
常白血球5種類とは異なる2次元サイトグラムが生じる
ため、上述の異型リンパ球や幼若顆粒球を含め異常球が
存在する血液標本を検出することが可能である。
By using the staining solution of the present invention, not only five normal leukocytes but also abnormal lymphocytes and immature granulocytes can be classified. For blood specimens with platelet aggregation including blast cells, a two-dimensional cytogram different from the 5 types of normal leukocytes is generated, so blood specimens with abnormal spheres including the above-mentioned atypical lymphocytes and immature granulocytes are detected. It is possible to

【0018】[0018]

【実施例】以下に、本発明の実施例を、発明の内容に応
じて実施例1〜実施例3に分けて具体的に説明する。 〔実施例1〕本発明における白血球分類ための染色条件
の代表的な例を下記の表に示す。緩衝液としては、ほう
酸ナトリウム塩酸系緩衝液を使用している。染色溶液の
浸透圧は290mosm/kgと生理的な浸透圧に調製
されている。染色溶液のpHは、生理的はpHより1乃
至それ以上高い値にすることにより、前記特開昭47−
3049号に開示された分析法による生理学的浸透圧条
件では、正常白血球を3種類しか分類できなかったが、
本組成にすることにより、正常白血球を5種類分類する
ことが可能となった。
EXAMPLES Examples of the present invention will be specifically described below by classifying them into Examples 1 to 3 according to the contents of the invention. [Example 1] The following table shows a representative example of staining conditions for classifying white blood cells in the present invention. As the buffer solution, a sodium borate-hydrochloric acid buffer solution is used. The osmotic pressure of the dyeing solution is adjusted to 290 mosm / kg, which is a physiological osmotic pressure. Physiologically, the pH of the dyeing solution is set to a value higher than pH by 1 or more, whereby the dyeing solution described in JP-A 47-
Under the physiological osmotic conditions of the analysis method disclosed in No. 3049, only three types of normal leukocytes could be classified,
With this composition, it became possible to classify 5 types of normal white blood cells.

【0019】[0019]

【表1】 [Table 1]

【0020】蛍光測定の装置構成は通常のフローサイト
メータと同一構成であり、レーザとしては発振波長48
8nmのアルゴン・イオンレーザを使用する。これは、
アクリジンオレンジの吸収極大波長に一致させるためで
ある。蛍光信号は、先に述べた緑色蛍光及び赤色蛍光波
長帯を光フィルタで選択し、光検出器で電気信号に変換
する。
The apparatus configuration for fluorescence measurement is the same as that of an ordinary flow cytometer, and the laser has an oscillation wavelength of 48.
An 8 nm argon ion laser is used. this is,
This is to match the absorption maximum wavelength of acridine orange. As for the fluorescence signal, the green fluorescence and red fluorescence wavelength bands described above are selected by an optical filter and converted into an electrical signal by a photodetector.

【0021】上記実施例において、本来、赤血球溶血剤
を添加しなくても、正常白血球の5種類の分類が可能で
ある。しかし、更に赤血球溶血剤として本実施例ではサ
ポニンを使用した。これにより、先に述べた赤血球によ
る散乱、吸収、及び蛍光の影響を改善することができ
る。サポニンの濃度は、表1に示した通り0.025〜
0.035重量%の割合で添加すると効果が大きい。
In the above-mentioned embodiment, five types of normal white blood cells can be classified essentially without adding a red blood cell hemolyzing agent. However, saponin was used in this example as the red blood cell hemolytic agent. This can improve the effects of scattering, absorption, and fluorescence by the red blood cells described above. The concentration of saponin is 0.025 ~ as shown in Table 1.
Addition in a proportion of 0.035% by weight has a great effect.

【0022】図1において、本実施例で得られた緑色蛍
光及び赤色蛍光に基づく正常白血球5種類のサイトグラ
ム(図1(a))と、溶血剤の有無による蛍光サイトグ
ラムの変化(図1(b),(c))を示した。図1を比
較することにより、溶血剤を添加しなくても十分に正常
白血球5種類の分類が可能であること、及び溶血剤添加
により各血球の分離が改善されていることが分かる。
In FIG. 1, cytograms of five types of normal white blood cells based on green fluorescence and red fluorescence obtained in this example (FIG. 1 (a)) and changes in fluorescence cytogram depending on the presence or absence of a hemolytic agent (FIG. 1). (B) and (c) are shown. By comparing FIG. 1, it can be seen that the five types of normal white blood cells can be sufficiently classified without adding a hemolytic agent, and that the addition of the hemolytic agent improves the separation of each blood cell.

【0023】〔実施例2〕赤血球溶血剤によって、光散
乱信号は、白血球細胞からだけのものが検出される。光
散乱信号は、前方散乱光と90度方向側方散乱光を使用
する。前方散乱光は血球のサイズ情報を、側方散乱信号
は細胞の内部情報に対応していることが知られている。
表1の染色条件を満たす染色溶液を使用したときの、光
散乱信号による白血球サイトグラムは、図2に示す如く
なった。図2において、横軸は側方散乱であり、縦軸は
前方散乱である。クラスタとしては、3つ存在する。す
なわち、リンパ球L及び好塩基球Bと、単球Mと、好酸
球E及び好中球Nの3つのクラスタからなるパターンで
ある。
[Embodiment 2] With the red blood cell hemolyzing agent, the light scattering signal is detected only from white blood cells. The light-scattering signal uses forward scattered light and 90-degree direction side-scattered light. It is known that the forward scattered light corresponds to blood cell size information and the side scattered signal corresponds to cell internal information.
The white blood cell cytogram by the light scattering signal when using the staining solution satisfying the staining conditions of Table 1 was as shown in FIG. In FIG. 2, the horizontal axis represents side scatter and the vertical axis represents forward scatter. There are three clusters. That is, it is a pattern composed of three clusters of lymphocytes L and basophils B, monocytes M, eosinophils E and neutrophils N.

【0024】この光散乱信号によるクラスタ情報と、前
述の蛍光によるサイトグラム情報を利用することによ
り、正常白血球の5分類の分類精度を改善することがで
きる。特に、光散乱信号では単球が独立したクラスタを
形成すること、及び、リンパ球と好塩基球が重なってい
るが、蛍光サイトグラムデータからリンパ球を正しく識
別できることから、好塩基球の数を正確に知ることがで
きる。
By using the cluster information based on the light scattering signal and the cytogram information based on the fluorescence described above, the classification accuracy of the five classifications of normal white blood cells can be improved. In particular, monocytes form independent clusters in the light-scattering signal, and lymphocytes and basophils overlap, but since the lymphocytes can be correctly identified from the fluorescence cytogram data, the number of basophils can be determined. You can know exactly.

【0025】〔実施例3〕実施例1で示した白血球の蛍
光サイトグラムには、正常白血球の5分類ばかりでな
く、異常球が存在する場合、この異常球も特定の位置に
存在することを見い出された。白血球蛍光サイトグラム
における、異常球に関する代表的な特徴パターンを図3
に示す。図3において、(a)は異型リンパ球(AT
L)の出現例を示し、(b)は幼若顆粒球(IMG)の
出現例を示し、(c)は血小板凝集の出現例を示す。
[Embodiment 3] In the fluorescence cytogram of white blood cells shown in the first embodiment, not only the five classifications of normal white blood cells but also the presence of abnormal spheres indicates that these abnormal spheres also exist at a specific position. Was found. Fig. 3 shows typical characteristic patterns of abnormal spheres in the white blood cell fluorescence cytogram.
Shown in. In FIG. 3, (a) is an atypical lymphocyte (AT
L) shows an appearance example, (b) shows an immature granulocyte (IMG) appearance example, and (c) shows a platelet aggregation appearance example.

【0026】図3(a)に示す如く、異型リンパ球は、
通常のリンパ球の上部(破線の円で示した箇所)、すな
わち緑色蛍光のより大きい位置に分布する。この事実か
ら、緑色蛍光強度のリンパ球位置の上部をデータ処理で
切り出すことにより、異型リンパ球の個数を決定でき
る。
As shown in FIG. 3 (a), the atypical lymphocytes are
It is distributed in the upper part of normal lymphocytes (the place indicated by the dashed circle), that is, in the position where the green fluorescence is larger. From this fact, the number of atypical lymphocytes can be determined by cutting out the upper part of the lymphocyte position of green fluorescence intensity by data processing.

【0027】図3(b)に示す如く、幼若顆粒球は、好
酸球の右側(破線の楕円で示した箇所)、赤色蛍光の大
なる位置に分布する。よって好中球より小さい緑色蛍光
であって、且つ好酸球より赤色強度が大なる領域を幼若
顆粒球と考えることにより、幼若顆粒球数を知ることが
できる。
As shown in FIG. 3 (b), immature granulocytes are distributed on the right side of eosinophils (the place indicated by the ellipse of the broken line) and at the position of large red fluorescence. Therefore, the number of immature granulocytes can be known by considering immature granulocytes as a region having a green fluorescence smaller than that of neutrophils and a red intensity higher than that of eosinophils.

【0028】これらの異型リンパ球又は幼若顆粒球に関
しては、実際の顕微鏡による目視結果と統計的誤差内で
識別結果が一致することを確かめた。
With regard to these atypical lymphocytes or immature granulocytes, it was confirmed that the results of discrimination by the actual microscope and the results of discrimination agree with each other within statistical error.

【0029】図3(c)に示す如く、血小板凝集が存在
する血液標本では、原点付近から右上がりの通常パター
ンとは異なるサイトグラムが重なって出現する。パター
ン認識手法などで処理することにより、この凝集パター
ンを検出することが可能である。同様なことは、芽球系
異常血球の出現している血液標本でも、通常正常白血球
クラスタと異なるパターンが現れ、パターン認識手法で
異常検体を検出することができる。
As shown in FIG. 3 (c), in a blood sample in which platelet aggregation is present, cytograms different from the normal pattern rising from the vicinity of the origin appear to overlap. This aggregation pattern can be detected by processing with a pattern recognition method or the like. Similarly, even in a blood sample in which abnormal blast cells have appeared, a pattern different from that of normal white blood cell clusters usually appears, and an abnormal sample can be detected by a pattern recognition method.

【0030】なお、前記実施例では、表1に示した緩衝
剤、溶血剤としてサポニン等を中心に記述してあるが、
その他の試薬において同一効果を有する緩衝剤、溶血剤
であれば本発明に含まれることは明らかである。また本
発明は、本発明による白血球分析方法による試薬を混合
した細胞分析試薬を含むものであり、細胞分析装置で本
試薬を用いて細胞分析を行ことができる。従って本発明
は、白血球の分類のみに限定されず、細胞分析方法とし
て一般的に適用することができるものである。
In the above-mentioned Examples, saponin and the like are mainly described as buffers and hemolytic agents shown in Table 1,
It is clear that the present invention includes any buffering agent or hemolytic agent having the same effect in other reagents. In addition, the present invention includes a cell analysis reagent in which reagents according to the leukocyte analysis method according to the present invention are mixed, and cell analysis can be performed using this reagent in a cell analyzer. Therefore, the present invention is not limited to the classification of white blood cells but can be generally applied as a cell analysis method.

【0031】[0031]

【発明の効果】以上の説明で明らかなように本発明によ
れば、次の効果を奏する。 (1)生理的等張条件で測定を行うことができるため、
白血球細胞への損傷が少なく、正しい白血球分類が行え
る。 (2)赤血球溶血剤により赤血球による吸収、散乱、蛍
光などの妨害影響を受けないため、各種白血球クラスタ
の分化が明瞭で、血球分類の正確度が向上する。 (3)染色時間を短縮でき、且つ採血後比較的短時間で
も各白血球の分画が可能である。 (4)蛍光強度が増大する。これは、信号検出能力を向
上させ、低出力レーザの使用を可能とする。 (5)赤血球を溶血させるため、白血球分類に光散乱の
情報も利用できる。 (6)以上の効果により、白血球正常5分類を高正確度
で且つ再現性良く分類識別することができる。 (7)異常白血球である異型リンパ球、幼若顆粒球の分
類を可能とし、更に芽球を含む異常血球検体や血小板凝
集検体の検出が可能である。
As is apparent from the above description, the present invention has the following effects. (1) Since the measurement can be performed under physiological isotonic conditions,
Accurate classification of white blood cells with less damage to white blood cells. (2) Since the red blood cell hemolyzing agent is not affected by the interference of absorption, scattering, fluorescence, etc. by red blood cells, the differentiation of various white blood cell clusters is clear and the accuracy of blood cell classification is improved. (3) The staining time can be shortened and each leukocyte can be fractionated in a relatively short time after blood collection. (4) The fluorescence intensity increases. This improves signal detection capability and allows the use of low power lasers. (5) Since the red blood cells are hemolyzed, light scattering information can be used for white blood cell classification. (6) With the above effects, the five normal white blood cell classifications can be classified with high accuracy and reproducibility. (7) It is possible to classify atypical lymphocytes, immature granulocytes, which are abnormal white blood cells, and further, it is possible to detect abnormal blood cell samples including blast cells and platelet aggregation samples.

【図面の簡単な説明】[Brief description of drawings]

【図1】白血球蛍光サイトグラムと溶血剤有無の効果を
示す説明図である。
FIG. 1 is an explanatory diagram showing the effects of leukocyte fluorescence cytogram and the presence or absence of a hemolytic agent.

【図2】光散乱信号による白血球サイトグラムの一例を
示す説明図である。
FIG. 2 is an explanatory diagram showing an example of a white blood cell cytogram based on a light scattering signal.

【図3】異常球が存在する血液標本の場合のサイトグラ
ムの一例を示す説明図である。
FIG. 3 is an explanatory diagram showing an example of a cytogram in the case of a blood sample containing abnormal spheres.

───────────────────────────────────────────────────── フロントページの続き (72)発明者 桜庭 伸一 茨城県勝田市市毛882番地 株式会社日立 製作所那珂工場内 (72)発明者 金子 紀夫 茨城県勝田市市毛882番地 株式会社日立 製作所那珂工場内 (72)発明者 多田羅 信之 茨城県勝田市市毛882番地 日立計測エン ジニアリング株式会社内 (72)発明者 大木 博 茨城県土浦市神立町502番地 株式会社日 立製作所機械研究所内 (72)発明者 山崎 功夫 茨城県土浦市神立町502番地 株式会社日 立製作所機械研究所内 (72)発明者 三宅 亮 茨城県土浦市神立町502番地 株式会社日 立製作所機械研究所内 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Shinichi Sakuraba 882 Ichige, Katsuta-shi, Ibaraki Hitachi, Ltd. Naka factory (72) Inventor Norio Kaneko 882, Ichige, Katsuta-shi, Ibaraki Hitachi, Ltd. Naka factory (72) Inventor Nobuyuki Tada No. 882 Ichimo, Katsuta City, Ibaraki Hitachi Measurement Engineering Co., Ltd. (72) Inventor Hiroshi Oki No. 502, Jinmachicho, Tsuchiura City, Ibaraki Prefectural Institute of Mechanical Engineering Co., Ltd. (72) Inventor Isao Yamazaki 502 Jintamachi Machinery Research Institute, Tsuchiura City, Ibaraki Prefecture, inside the Hiritsu Seisakusho Co., Ltd. (72) Inventor Ryo Miyake 502 Jinmachicho, Tsuchiura City, Ibaraki Pref.

Claims (5)

【特許請求の範囲】[Claims] 【請求項1】 レーザ光を利用するフロー式の白血球分
析方法において、予め白血球を染色するための分析蛍光
染色溶液として、 (1)アクリジンオレンジ蛍光染料 (2)溶液pHが生理的pHより高い緩衝液 (3)生理的等張浸透圧 からなる試薬を含むアクリジンオレンジ蛍光染色溶液を
使用し、白血球からの緑色蛍光及び赤色蛍光による蛍光
信号の大小により、血液中の白血球の分類を行うことを
特徴とする白血球分析方法。
1. A flow-type leukocyte analysis method using laser light, wherein (1) acridine orange fluorescent dye (2) a buffer having a solution pH higher than physiological pH, as an analytical fluorescent staining solution for previously staining leukocytes. Liquid (3) A white blood cell in blood is classified by using acridine orange fluorescent staining solution containing a reagent consisting of physiological isotonic osmotic pressure, and by the magnitude of the fluorescence signal from green fluorescence and red fluorescence from white blood cell. The method of leukocyte analysis.
【請求項2】 請求項1記載の白血球分析方法におい
て、前記アクリジンオレンジ蛍光染色溶液に含まれる前
記試薬が、 (1)アクリジンオレンジ蛍光染料 濃度 0.014
〜0.018 mM (2)溶液pH 8.4〜8.9の緩衝液 (3)浸透圧 290±10 mosm/kg からなることを特徴とする白血球分析方法。
2. The leukocyte analysis method according to claim 1, wherein the reagent contained in the acridine orange fluorescent staining solution is (1) acridine orange fluorescent dye concentration 0.014.
˜0.018 mM (2) solution pH 8.4 to 8.9 buffer (3) osmotic pressure 290 ± 10 mosm / kg.
【請求項3】 請求項1又は2記載の白血球分析方法に
おいて、前記アクリジンオレンジ蛍光染色溶液に、溶血
剤を添加したことを特徴とする白血球分析方法。
3. The leukocyte analysis method according to claim 1, wherein a hemolytic agent is added to the acridine orange fluorescent staining solution.
【請求項4】 請求項3記載の白血球分析方法におい
て、前記溶血剤としてサポニンを使用し、このサポニン
を0.025〜0.035重量%の割合で添加したこと
を特徴とする白血球分析方法。
4. The leukocyte analysis method according to claim 3, wherein saponin is used as the hemolytic agent, and the saponin is added in a proportion of 0.025 to 0.035% by weight.
【請求項5】 請求項1〜4のいずれか1項に記載され
た白血球分析用の前記アクリジンオレンジ蛍光染色溶液
を用いて、5種類の正常白血球を分類し、異常球として
異型リンパ球と幼若顆粒球を分類し、更に血小板凝集の
ある血液標本を検出することを特徴とする白血球分析方
法。
5. Using the acridine orange fluorescent staining solution for leukocyte analysis according to claim 1, 5 types of normal leukocytes are classified, and atypical lymphocytes and juvenile lymphocytes are classified as abnormal spheres. A leukocyte analysis method characterized by classifying juvenile granulocytes and further detecting a blood sample having platelet aggregation.
JP3090559A 1991-04-22 1991-04-22 White blood cell analysis method Expired - Lifetime JPH07113632B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3090559A JPH07113632B2 (en) 1991-04-22 1991-04-22 White blood cell analysis method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3090559A JPH07113632B2 (en) 1991-04-22 1991-04-22 White blood cell analysis method

Publications (2)

Publication Number Publication Date
JPH0599919A true JPH0599919A (en) 1993-04-23
JPH07113632B2 JPH07113632B2 (en) 1995-12-06

Family

ID=14001775

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3090559A Expired - Lifetime JPH07113632B2 (en) 1991-04-22 1991-04-22 White blood cell analysis method

Country Status (1)

Country Link
JP (1) JPH07113632B2 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10319010A (en) * 1997-05-19 1998-12-04 Toa Medical Electronics Co Ltd Reagent and method for laucocyte classification and counting
WO2004001408A1 (en) * 2002-06-24 2003-12-31 Sysmex Corporation Method of classifying and counting leucocytes
JP2007093356A (en) * 2005-09-28 2007-04-12 Sysmex Corp Blood imaging system, blood imaging method, treatment apparatus and imaging mainframe
JP2007139438A (en) * 2005-11-15 2007-06-07 Sysmex Corp Blood analyzer
WO2009001868A1 (en) * 2007-06-25 2008-12-31 Sysmex Corporation Reagent and reagent kit for analysis of primitive leukocyte
JP2009002963A (en) * 1997-05-13 2009-01-08 Sysmex Corp Particle measurement apparatus
JP2010249796A (en) * 2009-03-26 2010-11-04 Sysmex Corp Device, and method for analyzing blood, and computer program
JP2011002465A (en) * 2010-09-16 2011-01-06 Sysmex Corp Apparatus and method for imaging blood
EP2703813A1 (en) * 2011-04-28 2014-03-05 Sysmex Corporation Blood analyzer, blood analysis method, and computer program
JP2014520253A (en) * 2011-05-04 2014-08-21 アボット・ラボラトリーズ Basophil analysis system and method
US8859200B2 (en) 2007-06-25 2014-10-14 Sysmex Corporation Reagent and reagent kit for analysis of immature leukocyte
US9778163B2 (en) 2011-05-04 2017-10-03 Abbott Laboratories Nucleated red blood cell analysis system and method
US9778162B2 (en) 2011-05-04 2017-10-03 Abbott Laboratories White blood cell analysis system and method
CN112798567A (en) * 2021-02-01 2021-05-14 山东大学 Method for in-vitro detection of miRNA (micro ribonucleic acid) based on ratio fluorescence of acridine orange and carbon dots

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012088336A (en) * 2012-01-23 2012-05-10 Sysmex Corp Method and device for discriminating myeloblast from platelet aggregation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59853A (en) * 1977-03-23 1984-01-06 デユ−ロ−テスト・コ−ポレイシヨン Incandecent light source with transparent heat mirror
JPS6370166A (en) * 1986-09-10 1988-03-30 Toa Medical Electronics Co Ltd Classification of white corpuscle by flow sight metry

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59853A (en) * 1977-03-23 1984-01-06 デユ−ロ−テスト・コ−ポレイシヨン Incandecent light source with transparent heat mirror
JPS6370166A (en) * 1986-09-10 1988-03-30 Toa Medical Electronics Co Ltd Classification of white corpuscle by flow sight metry

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009002963A (en) * 1997-05-13 2009-01-08 Sysmex Corp Particle measurement apparatus
JP2011169916A (en) * 1997-05-13 2011-09-01 Sysmex Corp Apparatus and method for measuring particle
JPH10319010A (en) * 1997-05-19 1998-12-04 Toa Medical Electronics Co Ltd Reagent and method for laucocyte classification and counting
US7625730B2 (en) 2002-06-24 2009-12-01 Sysmex Corporation Method for classifying and counting leukocytes
US7923229B2 (en) 2002-06-24 2011-04-12 Sysmex Corporation Method of classifying and counting leukocytes
WO2004001408A1 (en) * 2002-06-24 2003-12-31 Sysmex Corporation Method of classifying and counting leucocytes
JP2007093356A (en) * 2005-09-28 2007-04-12 Sysmex Corp Blood imaging system, blood imaging method, treatment apparatus and imaging mainframe
JP4690163B2 (en) * 2005-09-28 2011-06-01 シスメックス株式会社 Blood imaging apparatus, blood imaging method, processing apparatus, and imaging main body apparatus
JP2007139438A (en) * 2005-11-15 2007-06-07 Sysmex Corp Blood analyzer
US8859200B2 (en) 2007-06-25 2014-10-14 Sysmex Corporation Reagent and reagent kit for analysis of immature leukocyte
JPWO2009001868A1 (en) * 2007-06-25 2010-08-26 シスメックス株式会社 Reagent for analysis of immature leukocytes and reagent kit for analysis
US8455209B2 (en) 2007-06-25 2013-06-04 Sysmex Corporation Reagent and reagent kit for analysis of immature leukocyte
WO2009001868A1 (en) * 2007-06-25 2008-12-31 Sysmex Corporation Reagent and reagent kit for analysis of primitive leukocyte
US9222934B2 (en) 2007-06-25 2015-12-29 Sysmex Corporation Reagent and reagent kit for analysis of immature leukocyte
JP2010249796A (en) * 2009-03-26 2010-11-04 Sysmex Corp Device, and method for analyzing blood, and computer program
JP2011002465A (en) * 2010-09-16 2011-01-06 Sysmex Corp Apparatus and method for imaging blood
EP2703813A1 (en) * 2011-04-28 2014-03-05 Sysmex Corporation Blood analyzer, blood analysis method, and computer program
EP2703813A4 (en) * 2011-04-28 2014-11-05 Sysmex Corp Blood analyzer, blood analysis method, and computer program
EP3159692A1 (en) * 2011-04-28 2017-04-26 Sysmex Corporation Blood analyzer, blood analysis method, and computer program
JP2014520253A (en) * 2011-05-04 2014-08-21 アボット・ラボラトリーズ Basophil analysis system and method
US9778163B2 (en) 2011-05-04 2017-10-03 Abbott Laboratories Nucleated red blood cell analysis system and method
US9778162B2 (en) 2011-05-04 2017-10-03 Abbott Laboratories White blood cell analysis system and method
US9810618B2 (en) 2011-05-04 2017-11-07 Abbott Laboratories Basophil analysis system and method
US10481073B2 (en) 2011-05-04 2019-11-19 Abbott Laboratories Basophil analysis system and method
US10481072B2 (en) 2011-05-04 2019-11-19 Abbott Laboratories Nucleated red blood cell analysis system and method
US10481071B2 (en) 2011-05-04 2019-11-19 Abbott Laboratories White blood cell analysis system and method
CN112798567A (en) * 2021-02-01 2021-05-14 山东大学 Method for in-vitro detection of miRNA (micro ribonucleic acid) based on ratio fluorescence of acridine orange and carbon dots

Also Published As

Publication number Publication date
JPH07113632B2 (en) 1995-12-06

Similar Documents

Publication Publication Date Title
US7674622B2 (en) Method for determination of nucleated red blood cells and leukocytes in a whole blood sample in an automated hematology analyzer
EP0483116B1 (en) Method of classifying leukocytes by flow cytometry and reagents used in the method
EP0185048B1 (en) Method and reagent system for four-population differential determination of leukocytes
US7625712B2 (en) Method for a fully automated monoclonal antibody-based extended differential
US7008792B2 (en) Method of measurement of nucleated red blood cells
US6114173A (en) Fully automated method and reagent composition therefor for rapid identification and characterization of reticulocytes erythrocytes and platelets in whole blood
JP4433611B2 (en) Identification method for nucleated red blood cells
US5776709A (en) Method for preparation and analysis of leukocytes in whole blood
EP0131020A1 (en) Method for the volumetric differentiation of leukocytes.
US6632676B1 (en) Multi-purpose reagent system and method for enumeration of red blood cells, white blood cells and thrombocytes and differential determination of white blood cells
Fujimoto Principles of measurement in hematology analyzers manufactured by Sysmex Corporation
JPH03266999A (en) Reagent for automatic flow sightmetry measurement of sub-population of at least one leukocyte from whole blood and measuring method using said reagent
US20040241769A1 (en) Multi-purpose reagent system and method for enumeration of red blood cells, white blood cells and thrombocytes and differential determination of white blood cells
JPH06100596B2 (en) Method for classifying leukocytes by flow cytometry
JPH0599919A (en) Leukocyte analyzing method
JP4087560B2 (en) How to identify erythroblasts
CN111684263A (en) Blood analysis system, blood analyzer, blood analysis method, and storage medium
US5179026A (en) Method of classifying leukocytes by flow cytometry and reagents used in the method
US20230296591A1 (en) Sample analysis method, sample analyzer, and computer-readable storage medium
CN114450589A (en) Method for analyzing red blood cells in blood sample and blood analysis system
CN110226083A (en) Red cell debris recognition methods and device, blood cell analyzer and analysis method
Ronot et al. Assessment of cell viability in mammalian cell lines
EP0259833A2 (en) Reagent and method for classifying leukocytes by flow cytometry
Lehner et al. Automation in hematology
JPS63134957A (en) Method for classifying white blood cell by flow cytometry

Legal Events

Date Code Title Description
FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20071206

Year of fee payment: 12

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081206

Year of fee payment: 13

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081206

Year of fee payment: 13

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 14

Free format text: PAYMENT UNTIL: 20091206

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101206

Year of fee payment: 15

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101206

Year of fee payment: 15

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 16

Free format text: PAYMENT UNTIL: 20111206

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 16

Free format text: PAYMENT UNTIL: 20111206